Russell Lake, MD
Family Medicine · Richmond Hill, GANPI 1104081082
Payments from drug & device makers
Across 366 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$928
- AbbVie$556
- AstraZeneca$531
- Amgen$487
- Boehringer Ingelheim$462
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,64499%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 73 | $1,041 |
| Lilly USA, LLC | 64 | $928 |
| AbbVie(2 entities) | 37 | $556 |
| AstraZeneca | 33 | $531 |
| Amgen(2 entities) | 29 | $487 |
| Boehringer Ingelheim | 24 | $462 |
| Pfizer | 25 | $361 |
| Esperion Therapeutics, Inc. | 11 | $178 |
| GSK | 7 | $135 |
| Sanofi-aventis U.S. LLC | 7 | $122 |
| Merck | 7 | $106 |
| Exact Sciences | 6 | $88 |
| Amarin Pharma, Inc. | 5 | $79 |
| Eisai Inc. | 4 | $66 |
| Kowa Pharmaceuticals America, Inc. | 5 | $63 |
| Daiichi Sankyo Inc. | 4 | $60 |
| Biohaven Pharmaceuticals, Inc. | 3 | $57 |
| Dexcom, Inc. | 3 | $56 |
| Novartis | 2 | $37 |
| Astellas Pharma US Inc | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 3 | $34 |
| Bayer | 2 | $31 |
| Johnson & Johnson | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Boston Scientific | 1 | $22 |
| Antares Pharma, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$5,690 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 71 | $91,107 |
| OzempicSemaglutide | 57 | $79,352 |
| JardianceEmpagliflozin | 59 | $77,529 |
| MounjaroTirzepatide | 67 | $77,110 |
| EliquisApixaban | 85 | $76,598 |
| FarxigaDapagliflozin Propanediol | 57 | $63,483 |
| RybelsusSemaglutide | 29 | $44,793 |
| Dupixent PenDupilumab | 12 | $44,650 |
| JanuviaSitagliptin Phosphate | 26 | $32,670 |
| XareltoRivaroxaban | 35 | $27,133 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $20,056 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $19,000 |
| Repatha SureclickEvolocumab | 23 | $17,952 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $17,508 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $14,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $928 | $168,216138 claims |
| Novo NordiskOzempic, Rybelsus | $1,041 | $124,14586 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $462 | $86,81773 claims |
| PfizerEliquis | $361 | $76,59885 claims |
| AstraZenecaFarxiga | $531 | $63,48357 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $135 | $33,24053 claims |
| MerckJanuvia | $106 | $32,67026 claims |
| Johnson & JohnsonXarelto | $31 | $27,13335 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $122 | $17,50814 claims |
| AbbVieSynthroid | $556 | $1,60029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Richmond Hill
- Rebecca SellersRichmond Hill$47K
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.